253 related articles for article (PubMed ID: 32631634)
1. Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
Evelina Cardoso ; Guidi M; Khoudour N; Pascaline Boudou-Rouquette ; Fabre E; Tlemsani C; Arrondeau J; François Goldwasser ; Vidal M; Schneider MP; Wagner AD; Widmer N; Blanchet B; Csajka C
Clin Ther; 2020 Jul; 42(7):1302-1316. PubMed ID: 32631634
[TBL] [Abstract][Full Text] [Related]
2. Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer.
van Leeuwen RW; Peric R; Hussaarts KG; Kienhuis E; IJzerman NS; de Bruijn P; van der Leest C; Codrington H; Kloover JS; van der Holt B; Aerts JG; van Gelder T; Mathijssen RH
J Clin Oncol; 2016 Apr; 34(12):1309-14. PubMed ID: 26858332
[TBL] [Abstract][Full Text] [Related]
3. Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non-Small Cell Lung Cancer.
Ohgami M; Kaburagi T; Kurosawa A; Doki K; Shiozawa T; Hizawa N; Homma M
Ther Drug Monit; 2018 Dec; 40(6):699-704. PubMed ID: 29995672
[TBL] [Abstract][Full Text] [Related]
4. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old.
Bigot F; Boudou-Rouquette P; Arrondeau J; Thomas-Schoemann A; Tlemsani C; Chapron J; Huillard O; Cessot A; Vidal M; Alexandre J; Blanchet B; Goldwasser F
Invest New Drugs; 2017 Apr; 35(2):242-246. PubMed ID: 27796680
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.
Fukudo M; Ikemi Y; Togashi Y; Masago K; Kim YH; Mio T; Terada T; Teramukai S; Mishima M; Inui K; Katsura T
Clin Pharmacokinet; 2013 Jul; 52(7):593-609. PubMed ID: 23532985
[TBL] [Abstract][Full Text] [Related]
7. Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.
Miyamoto S; Azuma K; Ishii H; Bessho A; Hosokawa S; Fukamatsu N; Kunitoh H; Ishii M; Tanaka H; Aono H; Nakahara Y; Kusaka K; Hosomi Y; Kikuchi N; Mori Y; Itani H; Hamada A; Yamada K; Okamoto H
JAMA Oncol; 2020 Jul; 6(7):e201250. PubMed ID: 32407455
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer.
Emoto-Yamamoto Y; Iida S; Kawanishi T; Fukuoka M
J Clin Pharm Ther; 2015 Apr; 40(2):232-9. PubMed ID: 25402940
[TBL] [Abstract][Full Text] [Related]
9. Correlation of plasma erlotinib trough concentration with skin rash in Chinese NSCLC patients harboring exon 19 deletion mutation.
Liao D; Yao D; Liu N; Cao L; Xiang D; Yang N; Zhang Y; Jiang W; Zhou C
Cancer Chemother Pharmacol; 2018 Sep; 82(3):551-559. PubMed ID: 30039303
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS).
Smit EF; Wu YL; Gervais R; Zhou C; Felip E; Feng J; Guclu SZ; Hoiczyk M; Dorokhova E; Freudensprung U; Grange S; Perez-Moreno PD; Mitchell L; Reck M
Lung Cancer; 2016 Sep; 99():94-101. PubMed ID: 27565921
[TBL] [Abstract][Full Text] [Related]
11. Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke.
Waller LL; Miller AA; Petty WJ
Lung Cancer; 2010 Jan; 67(1):12-6. PubMed ID: 19762110
[TBL] [Abstract][Full Text] [Related]
12. Lack of effect of smoking status on axitinib pharmacokinetics in patients with non-small-cell lung cancer.
Garrett M; Taylor T; Mould DR; Amantea MA; Chen Y; Ingrosso A; Pithavala YK
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1131-1141. PubMed ID: 27783139
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model.
Wu Q; Li MY; Li HQ; Deng CH; Li L; Zhou TY; Lu W
Acta Pharmacol Sin; 2013 Nov; 34(11):1427-36. PubMed ID: 24096601
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
Schmid U; Liesenfeld KH; Fleury A; Dallinger C; Freiwald M
Cancer Chemother Pharmacol; 2018 Jan; 81(1):89-101. PubMed ID: 29119292
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II Study of Erlotinib to Determine the Optimal Dose in Patients With Non-Small Cell Lung Cancer Harboring Only EGFR Mutations.
Takeda Y; Ishizuka N; Sano K; Hirano S; Suzuki M; Naka G; Sugiyama H
Clin Transl Sci; 2020 Nov; 13(6):1150-1160. PubMed ID: 32315488
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters.
Endo-Tsukude C; Sasaki JI; Saeki S; Iwamoto N; Inaba M; Ushijima S; Kishi H; Fujii S; Semba H; Kashiwabara K; Tsubata Y; Hayashi M; Kai Y; Saito H; Isobe T; Kohrogi H; Hamada A
Biol Pharm Bull; 2018; 41(1):47-56. PubMed ID: 29311482
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors.
Reddick SJ; Campagne O; Huang J; Onar-Thomas A; Broniscer A; Gajjar A; Stewart CF
Cancer Chemother Pharmacol; 2019 Oct; 84(4):829-838. PubMed ID: 31392390
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Drug Monitoring of Erlotinib in Non-Small Cell Lung Carcinoma: A Case Study.
Catalán-Latorre A; Sureda M; Brugarolas-Masllorens A; Escudero-Ortiz V
Ther Drug Monit; 2021 Aug; 43(4):447-450. PubMed ID: 33840795
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib in non-small-cell lung cancer.
Gridelli C; Rossi A; Maione P; Colantuoni G; Del Gaizo F; Ferrara C; Nicolella D; Guerriero C
Expert Opin Pharmacother; 2007 Oct; 8(15):2579-92. PubMed ID: 17931092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]